NSN "Neurosona Prepares for Clinical Trials in the US with Harvard Medical School Hospital"

[Asia Economy Reporter Hyunseok Yoo] NSN announced on the 16th that its subsidiary, Neurosona, a brain disease treatment device development company, signed a research support agreement on the 2nd with Spaulding Rehabilitation Hospital, affiliated with Harvard Medical School in the United States.

Through this agreement, Spaulding Rehabilitation Hospital will conduct preliminary clinical research using the Low-Intensity Focused Ultrasound stimulation system developed by Neurosona, and plans to apply for FDA approval for clinical trial use of Neurosona's device.

Spaulding Rehabilitation Hospital, located in Boston, USA, is one of the hospitals under Harvard Medical School and was ranked 3rd among rehabilitation hospitals in the United States (according to the 2019 U.S. News and World Report). The principal investigator of the research, Dr. Felipe Fregni, M.D., serves as the director of the Spaulding Neuromodulation Center. According to the company, he is an authority on chronic neuropsychiatric disorders using brain stimulation technology.

A Neurosona representative stated, "This research support agreement is part of Neurosona's preparation process for clinical trials in the United States. After obtaining FDA approval for clinical trial use, we plan to conduct clinical trials in the U.S. through Spaulding Rehabilitation Hospital for stroke patient treatment and improvement of motor skills in the general population."

The Low-Intensity Focused Ultrasound stimulation system developed by Neurosona can precisely treat specific deep brain areas without risky surgery for intractable brain diseases that have limited treatment effects or no suitable treatment alternatives. It has recently attracted great expectations and interest among researchers in brain disease.

Neurosona began research and development as NSN's bio business division by signing a research support agreement in August 2016 with BWH (Brigham and Women’s Hospital), an affiliated hospital of Harvard Medical School. To achieve greater growth as a bio company, it was spun off under the name Neurosona in August 2017.

Currently, Neurosona is conducting exploratory clinical trials evaluating the therapeutic efficacy and safety of the Low-Intensity Focused Ultrasound stimulation system for patients with Alzheimer's disease, major depression, and neuropathic pain. NSN is the largest shareholder, holding 54.8% of Neurosona's shares.

This content was produced with the assistance of AI translation services.